secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001299130-23-000135
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio Q3 revenue $55.7M (+72% YoY); net loss narrows to $66.9M
---------------------------------------------------------------

- Revenue $55.7M, up 72% YoY; instrument revenue $34.7M from 52 Revio systems (prior year $11.4M).
- Consumables revenue $16.9M (record; +5% YoY) with Revio consumables surpassing Sequel II/IIe.
- GAAP net loss $66.9M ($0.26/shr) vs $77.0M ($0.34/shr) prior year; Non-GAAP net loss $67.9M ($0.27).
- Gross margin 32% vs 42% prior year; non-GAAP gross margin also 32%.
- Cash and investments $767.8M; launched leasing program, first Onso shipments, and new WGS variant pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913023000135/0001299130-23-000135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913023000135/pacb-20231030.htm
  HTML page:      https://secwatch.observer/filing/0001299130-23-000135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer